Pricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. FCF margin (%)

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥6.3B
P/E ratio
-5.2x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndFCF margin (%) YoY (%)
Mar 31, 2025-110,479.2-93.16%
Mar 31, 2024-1,615,436.1+6976.04%
Mar 31, 2023-22,829.7+129.96%
Mar 31, 2022-9,927.8-86.23%
Mar 31, 2021-72,075.4+330.53%
Mar 31, 2020-16,741.1+1499.52%
Mar 31, 2019-1,046.6+118.26%
Mar 31, 2018-479.5+118.05%
Mar 31, 2017-219.9+94.26%
Mar 31, 2016-113.2+90.71%
Mar 31, 2015-59.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat